These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
275 related articles for article (PubMed ID: 32505262)
1. Periprocedural Management of Oral Anticoagulation. Shaw JR; Kaplovitch E; Douketis J Med Clin North Am; 2020 Jul; 104(4):709-726. PubMed ID: 32505262 [TBL] [Abstract][Full Text] [Related]
2. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation. Nazha B; Pandya B; Cohen J; Zhang M; Lopes RD; Garcia DA; Sherwood MW; Spyropoulos AC Circulation; 2018 Oct; 138(14):1402-1411. PubMed ID: 29794081 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of the efficacy of direct oral anticoagulants (DOACs) in comparison to warfarin in morbidly obese patients. Kalani C; Awudi E; Alexander T; Udeani G; Surani S Hosp Pract (1995); 2019 Oct; 47(4):181-185. PubMed ID: 31580732 [No Abstract] [Full Text] [Related]
4. Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation. Armbruster HL; Lindsley JP; Moranville MP; Habibi M; Khurram IM; Spragg DD; Berger RD; Calkins H; Marine JE Ann Pharmacother; 2015 Mar; 49(3):278-84. PubMed ID: 25515868 [TBL] [Abstract][Full Text] [Related]
5. Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience. Eikelboom J; Merli G Am J Med; 2016 Nov; 129(11S):S33-S40. PubMed ID: 27586367 [TBL] [Abstract][Full Text] [Related]
6. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population. Amin A; Keshishian A; Trocio J; Dina O; Le H; Rosenblatt L; Liu X; Mardekian J; Zhang Q; Baser O; Vo L Curr Med Res Opin; 2017 Sep; 33(9):1595-1604. PubMed ID: 28635338 [TBL] [Abstract][Full Text] [Related]
7. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. Douketis JD; Healey JS; Brueckmann M; Eikelboom JW; Ezekowitz MD; Fraessdorf M; Noack H; Oldgren J; Reilly P; Spyropoulos AC; Wallentin L; Connolly SJ Thromb Haemost; 2015 Mar; 113(3):625-32. PubMed ID: 25472710 [TBL] [Abstract][Full Text] [Related]
8. Comparative study of hemorrhagic and ischemic complications among anticoagulants in patients undergoing cryoballoon ablation for atrial fibrillation. Okishige K; Nakamura T; Aoyagi H; Kawaguchi N; Yamashita M; Kurabayashi M; Suzuki H; Asano M; Shimura T; Yamauchi Y; Sasano T; Hirao K J Cardiol; 2017 Jan; 69(1):11-15. PubMed ID: 27160710 [TBL] [Abstract][Full Text] [Related]
9. A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation. Feldberg J; Patel P; Farrell A; Sivarajahkumar S; Cameron K; Ma J; Battistella M Nephrol Dial Transplant; 2019 Feb; 34(2):265-277. PubMed ID: 29509922 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243 [No Abstract] [Full Text] [Related]
11. Comparing the Efficacy and Safety of Direct Oral Anticoagulants With Warfarin in the Morbidly Obese Population With Atrial Fibrillation. Kido K; Ngorsuraches S Ann Pharmacother; 2019 Feb; 53(2):165-170. PubMed ID: 30130979 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation. Martinez BK; Sood NA; Bunz TJ; Coleman CI J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29654196 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation. Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905 [TBL] [Abstract][Full Text] [Related]
14. Anticoagulation management in nonvalvular atrial fibrillation: current and future directions. Kornej J; Potpara T; Lip GY Pol Arch Med Wewn; 2013; 123(11):623-34. PubMed ID: 24104195 [TBL] [Abstract][Full Text] [Related]
15. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups. Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548 [TBL] [Abstract][Full Text] [Related]
16. Thrombotic complications with interruption of direct oral anticoagulants in dermatologic surgery. Siscos SM; Neill BC; Singh AH; Hocker TLH J Am Acad Dermatol; 2021 Feb; 84(2):425-431. PubMed ID: 33045293 [TBL] [Abstract][Full Text] [Related]
17. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban. Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583 [TBL] [Abstract][Full Text] [Related]
18. Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation. Jacobs V; May HT; Bair TL; Crandall BG; Cutler MJ; Day JD; Mallender C; Osborn JS; Stevens SM; Weiss JP; Woller SC; Bunch TJ Am J Cardiol; 2016 Jul; 118(2):210-4. PubMed ID: 27236255 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack. Coleman CI; Peacock WF; Bunz TJ; Alberts MJ Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814 [TBL] [Abstract][Full Text] [Related]
20. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting. Zheng Y; Sorensen SV; Gonschior AK; Noack H; Heinrich-Nols J; Sunderland T; Kansal AR Clin Ther; 2014 Dec; 36(12):2015-2028.e2. PubMed ID: 25438722 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]